Ensayos clínicos

Inclusion Criteria:

• Absolute neutrophil count (ANC) >= 1500/mm^3
• Platelet count (PLT) >= 100,000/mm^3
• Creatinine =< 2 x upper limit of normal (ULN)
• Either serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) or serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 1.5 x ULN
• Total/direct bilirubin =< 1.5 x ULN
• Alkaline phosphatase =< 1.5 x ULN
• Hemoglobin >= 9 mg/dL
• Negative urine or serum pregnancy test performed =< 7 days prior to registration, for women of childbearing potential only
• Previously experienced paclitaxel induced pain during a current or past paclitaxel treatment that the treating healthcare provider thinks is consistent with the paclitaxel-induced acute pain syndrome; note: formal documentation of prior pain is not required
• Scheduled to receive paclitaxel at a dose >= 70 mg/m^2 =< 14 days from randomization
• Ability to complete the questionnaires or to do so with assistance

Exclusion Criteria:

• Pregnant women
• Nursing women
• Any woman of childbearing potential or male partner of a woman of childbearing potential unwilling to employ acceptable contraception throughout the study and for at least 30 days after the last dose of the study drug
• History of gold-induced disorders, including but not limited to, necrotizing enterocolitis, pulmonary fibrosis, exfoliative dermatitis, bone marrow aplasias or other severe hematologic disorders; history of severe allergic or anaphylactic reactions or hypersensitivity to auranofin or other gold compounds
• Currently receiving Dilantin (phenytoin) or auranofin or another gold-containing compound
• Anticipated use of filgrastim (G-CSF) or sargramostim (GM-CSF) within 30 days after receiving auranofin
• Currently receiving immune-modulating therapies